We describe the complete exon-intron structure of the human elastin (ELN) gene located at chromosome 7q11.23. There are 34 exons occupying ∼47 kb of genomic DNA. All exons are in-frame, allowing exon skipping without disrupting the reading frame. Microsatellites are located in introns 17 and 18. Deletions of all or large parts of the ELN gene have been previously reported in two patients with supravalvular aortic stenosis (SVAS), and SVAS is also a frequent feature of Williams syndrome, where patients are hemizygous for ELN. We list primer pairs for amplifying each exon, with flanking intron, from genomic DNA to allow detection of point mutations in the ELN gene. We show that some patients with isolated SVAS have point mutations that are predicted to lead to premature chain termination. Knowledge of the genomic structure will allow more extensive mutation screening in genomic DNA of patients with SVAS and other conditions.
INTRODUCTION
The protein elastin is responsible for the characteristic elastic properties of many tissues including skin, lung and large blood vessels. The elasticity of these tissues depends on elastic fibres in the extracellular matrix. These are composed of an amorphous and a microfibrillar component, and the amorphous component (∼90% of the mature elastic fibre) is composed of elastin. The human elastin cDNA has been isolated and sequenced (1) . Early reports that ELN mapped to chromosome 2 proved mistaken; it maps to 7q11.2 (2) and has 34 exons. Comparative studies showed that the human cDNA lacks sequences corresponding to exons 34 and 35 of the bovine elastin gene, so that human exon 34 is homologous to bovine exon 36 (1) .
The initial product of the ELN gene is tropoelastin, a 72 kDa polypeptide with a characteristic primary structure of alternating hydrophobic and cross-linking domains. The hydrophobic domains are thought to form a floppy structure of stacked β-sheets with β-turns that is responsible for the resilience of the protein.
After secretion, individual tropoelastin chains are covalently cross-linked to form a highly insoluble network of elastic fibres. Cross-linking requires oxidation of lysyl residues by the copper-dependent enzyme lysyl oxidase (3) (4) (5) . Alanine(A)-lysine(K) rich motifs (A 3-10 KA 2-3 K) occur in the cross-linking domains in exons 15, 17, 19, 21, 23, 27 , 29 and 31, and in modified form in exons 6 and 25.
Since elastin is a major component of the aorta and large arteries, disruption of the elastin gene might be expected to cause vascular problems. One candidate condition is supravalvular aortic stenosis (SVAS) (6) . SVAS is a congenital narrowing of the ascending aorta. The condition is frequently progressive and may lead to heart failure and early death, so that patients often need corrective surgery in early infancy. SVAS may occur sporadically or as a familial condition with autosomal dominant inheritance (7) . Linkage analysis mapped familial SVAS to chromosome 7q (8) and a family in which a translocation t(6:7)(p21.1;q11.23) co-segregated with SVAS showed disruption of the elastin gene at 7q11.23 (9, 10) . Subsequently large intragenic deletions involving the elastin gene have been reported in two unrelated SVAS patients (11, 12) . SVAS also occurs as part of Williams syndrome (WS). WS (MIM 194050 ) is a contiguous gene syndrome caused by a microdeletion at 7q11.23 (13) . WS patients are hemizygous for the elastin gene. Affected individuals are mentally retarded but with an unusual cognitive profile (they speak fluently but have poor visuospatial skills). They have dysmorphic facies, frequently heart abnormalities (mainly SVAS), short stature, hyperacusis, and often infantile hypercalcaemia. Other connective tissue phenotypes associated with WS include hernias, hoarse voice, joint abnormalities, and premature ageing of skin.
SVAS is very variable, both in familial dominant SVAS and amongst patients with Williams syndrome. Nickerson et al. (14) report that the elastin deletion is seen in ∼90% of Williams syndrome patients, and in our experience, all patients with a classic WS phenotype are hemizygous at the elastin locus (unpublished data abnormalities at the ELN locus, what types of ELN mutations can cause SVAS, and whether other categories of ELN mutation might cause different connective tissue problems. To address these issues and allow screening of genomic DNA for mutations, we have determined the complete genomic structure of the human ELN gene. Until now, only partial exon-intron structures have been available in the literature (1) or in databases. In this study we have defined the unpublished exon-intron boundaries of the elastin gene and have carried out mutation screening in patients with dominant SVAS. We show that point mutations in the elastin gene can cause SVAS.
RESULTS

Structure of the elastin gene
We isolated a 125 kb bacterial artificial chromosome (BAC) containing the complete ELN coding sequence from a commercial library (Genosys), by screening with primers designed from the 5′ and 3′ ends of the published elastin cDNA sequence (1) . We used fluorescent in situ hybridisation (FISH) to confirm that the BAC mapped to 7q11.23 (data not shown). To define the unpublished exon-intron boundaries of the ELN gene, PCR primers were designed randomly using the last published exon boundary from the 3′ end of the human cDNA sequence (1) as a starting point, and PCR products from genomic DNA were sized and sequenced. In cases where no amplification was obtained between a set of primers, the vectorette method was used to define exon boundaries, as described by Riley et al. (15) . Primers designed from the intronic sequence were used to amplify each exon from genomic DNA, and in each case gave a product of the expected size. Our method of analysis leaves open the possibility that some transcripts might contain additional exons not present in the published cDNA sequence we relied on, such as the bovine exon 34 and 35 sequences that are missing from the published human sequence. Figure 1 shows the complete ELN cDNA sequence with exon-intron boundaries marked, and Table 1 summarises the splice junctions and surrounding sequence in the elastin gene. The coding sequence we have determined agrees with that published by Indik et al. (1) . It comprises 2361 bp (including the termination codon) split into 34 small exons ranging in size from 30 to 225 bp and extending over ∼47 kb of genomic sequence. The introns range from 82 bp to ∼10 kb, and all the exon-intron boundaries conform to the published consensus sequences (16) . Twenty-seven out of the 33 codons split by introns encode glycine residues (Table 1 ).
Alu and microsatellite repeats
As previously reported (17) , the 3′ region of the gene is rich in Alu sequences. A BLAST search of our sequence showed that introns Table 1 . Structure of the elastin gene X = cross-linking domain. *Subject to alternative splicing. C = C-terminal exon containing conserved cysteines and four basic residues; corresponds to exon 36 of bovine elastin. The polymorphic microsatellite in intron 18 is indicated as (gt)n. It has 17-20 repeats. A second microsatellite, (AG)n, is present in intron 17 ∼230 bp upstream of the 3′ end. 18, 19, 22, 27, 30 , 32 and 33 gave high homology with Alu-like sequences, especially Alu J and Alu Sx. Introns 30 (∼50% Alu), 32 (∼40% Alu) and 33 (∼33% Alu) were particularly rich in Alu-like sequences.
Intron sequencing detected two microsatellite repeats. An (AG) n repeat was located ∼230 bp upstream of the 5′ acceptor splice site of exon 18. At 10 bp downstream from the 3′ donor splice site of exon 18 is a (GT) [17] [18] [19] [20] repeat. This latter repeat has been reported previously (2; because of ambiguity in numbering of exons, it was said to be in intron 17) , and is polymorphic with heterozygosity 0.626.
Mutations in SVAS patients
Patients with diagnosed SVAS were analysed for mutations in the elastin gene. Intronic primers were designed to amplify each of the 34 exons from genomic DNA ( Table 2 ). Mutations were sought by combined single-strand conformation polymorphism (SSCP) and heteroduplex analysis (18) . Where bands of abnormal mobility were seen, the relevant exon was sequenced.
Patient SVAS12 presented at birth with a heart murmur. Cardiac catheterisation was thought to show obstruction, and an initial diagnosis of hypertrophic obstructive cardiomyopathy was made. The patient was seen at another centre at the age of 3 years for assessment of his heart murmur. Echocardiography suggested SVAS on the basis of waisting of the ascending aorta and post-stenotic dilatation. Subsequent cardiac catheterisation revealed a significant pressure gradient (106 mm Hg) between his left ventricle and aorta. At surgery he was found to have severe SVAS, a thickened aortic valve, stenosis at the origin of the right pulmonary artery, subvalvular infundibular pulmonary stenosis and severe left ventricular hypertrophy. He did not have the facial features of WS, and his psychomotor development was normal. Of significance in the family history, his brother died suddenly in the first year of life and at autopsy was noted to have repaired SVAS, repaired central pulmonary artery stenosis and marked ventricular hypertrophy. The aortic valve and proximal aorta were markedly dysplastic with extreme thickening beyond the valve. The proband's mother had presented to cardiologists in childhood with a murmur and a clinical diagnosis of aortic stenosis was made.
SVAS12 showed no evidence of a large deletion: elastin FISH (WSCR probe, Oncor) was normal. Amplified DNA gave an abnormal band in exon 26 on heteroduplex analysis, which was Table 2 . Primer sequences for the amplification of exons 1-34 of the human elastin gene not present in 40 non-SVAS controls (Fig. 2) . Sequencing revealed insertion of a T base in codon 606 of exon 26, producing a frameshift predicted to cause premature termination 10 codons downstream: Normal allele:
Mutant allele:
The mutation was confirmed by designing an allele-specific ARMS primer to allow selective amplification of the mutant allele (19) . ARMS amplification and sequencing showed that the proband's mother also has the mutation (Fig. 2) .
Patient SVAS50 presented at the age of 8 weeks with a heart murmur and episodes of cyanosis. Echocardiography at 4 months of age showed SVAS and pulmonary arterial stenosis. This was progressive and cardiac catheterisation at 18 months showed a left ventricular pressure of 142 mm Hg with a pull back gradient of 66 mm Hg from left ventricle to aorta at the supravalvular level. There was no gradient at the level of the aortic valve. The right ventricular systolic pressure and branch pulmonary artery pressures were 76 and 15 mm Hg respectively although the catheter wedged very quickly in the branch pulmonary arteries because of the very small size of the branch vessels. Angiography showed the supravalvular aortic narrowing and the very abnormal pulmonary arteries. Corrective open heart surgery was performed at the age of 21 months and at this time it was noted that the aorta and pulmonary arteries were very thick and abnormal. His developmental progress is normal to date and he has no features of Williams syndrome. His mother had cardiac follow up for a heart murmur until the age of 6 years, but a recent echocardiogram showed no evidence of supravalvular aortic stenosis and no pulmonary artery stenosis.
Patient SVAS50 showed no evidence of a large deletion: elastin FISH (WSCR probe, Oncor) was normal. Heteroduplex-SSCP analysis showed a heteroduplex shift in exon 21 which was not present in 43 normal controls. Sequence analysis revealed a single base substitution (CAG→TAG) in codon 442 which changed a glutamine to a stop codon (Q442X). This mutation creates a HindIII site, allowing us to confirm the mutation by restriction digest analysis:
Normal allele:
Mutant allele (HindIII site underlined): The PCR product from the normal allele is not digested (275 bp), whereas the mutant allele gives two restriction fragments of 150 bp and 125 bp (Fig. 3) . Restriction digest analysis and sequencing showed that the Q442X mutation was also present in the mother's DNA (Fig. 3) .
DISCUSSION
Elastin is an important structural component of the aorta and pulmonary arteries. The walls of these large elastic vessels are primarily composed of alternating layers of smooth muscle and elastic fibres. Two theories explaining the molecular pathology of SVAS can be proposed: the defects in elastin could be qualitative or quantitative. Evidence favouring a quantitative mechanism rather than production of abnormal elastin, as the pathogenic mechanism in SVAS includes the fact that Williams syndrome (WS) patients are hemizygous for elastin because of a chromosomal microdeletion, and these patients are at high risk of SVAS. Also elastin mutations reported so far in patients with isolated SVAS have been disruptions or large deletions. Curran et al. (9) reported a family segregating a balanced translocation t(6:7)(p21.1;q11.23) with a breakpoint in intron 27 of the ELN gene. Ewart et al. (11) described a 100 kb deletion in an SVAS patient, which deleted all 3′ ELN sequences from exon 28. Olson et al. (12) reported a patient with severe SVAS who had a 30 kb intragenic deletion that removed exons 2-27 of the elastin gene whilst maintaining the 3′ terminus intact. Our two SVAS patients have point mutations that are predicted to truncate the transcript in exon 21 or exon 26. ELN transcripts lacking the 3′ terminus may be unstable or poorly translated. High sequence homology (80%) in the 3′ untranslated region in different species suggests that it has an important conserved function and may play a role in stabilising the mature mRNA or in modulating translation (20) . Finally, variable expressivity and reduced penetrance of SVAS is seen both in Williams syndrome and familial isolated SVAS. SVAS varies from subtle cardiac abnormalities to severe stenosis of multiple arteries, although there is no evidence of locus heterogeneity. In our two SVAS families with point mutations, each mutation manifests as severe SVAS in the proband, but as mild cardiac features or non-penetrance in the mothers. Such variability is typical of phenotypes produced by haploinsufficiency, where genetic background is expected to have a major modifying effect.
The alternative hypothesis is that a dominant negative elastin mutation could result in SVAS. Research into the assembly of elastic fibres suggests that the C-terminus of tropoelastin mediates elastin polymerisation through interaction with microfibril-associated glycoproteins (MAGP) (21) . If the mutant elastin genes described above are expressed, truncated proteins would probably be produced that would lack several important features. These include consensus sites for desmosine crosslinking, exon 36 (which contains important functional domains), and also the two highly conserved cysteine residues in exon 34 thought to be important for interaction with fibrillin in arrays of microfibrils, as well as a MAGP binding domain. Truncated proteins in which some but not all domains critical for intermolecular interaction are absent may disrupt post-translational processing and consequently, the development of elastic fibres.
It is possible that SVAS arises as a result of both mechanisms, depending on the particular mutation involved. Haploinsufficiency of elastin, where a half dose of normal elastin is being produced, or abnormal elastic fibres arising from dominant negative elastin mutations, could both manifest as SVAS. It is intriguing that WS patients show a wider range of connective tissue phenotypes than SVAS patients-whether this is caused by deletion or silencing of other adjacent genes remains to be seen. Human Molecular Genetics, 1997 , Vol. 6, No. 7 1035 However, no obvious phenotype-genotype correlation has emerged in SVAS.
Elucidating the molecular pathogenesis of SVAS may also have implications for treatment. Pre-natal diagnosis can be offered to families with autosomal dominant SVAS to allow early diagnosis and treatment. At present vascular surgery is the only treatment for SVAS; however, it has been suggested that early intervention with drug treatment to lower the heart rate and blood pressure may slow progression of the disease (9) . The use of elastase inhibitors in preventing pulmonary hypertension and associated pulmonary arterial abnormalities is also being investigated (23) .
Defining the elastin gene structure has allowed us to identify the first point mutations that cause SVAS and will enable us to carry out mutation screening on a larger scale. Continued mutation analysis in SVAS and WS patients may help distinguish the vascular pathology of these conditions, and will allow other conditions to be investigated for involvement of elastin mutations.
MATERIALS AND METHODS
Exon-intron structure of ELN
A 125 kb BAC clone containing the elastin gene was isolated from a BAC library (Genosys) by PCR screening with primers P1-P2 and P3-P4, designed from the ELN cDNA sequence:
5′ CCG GGA TAA AAC GAG GTG CGG GAG Primer P2:
5′ TCC AGG CCG AGA GGG GTG GAG GAT Primer P3:
5′ AGC CGA AAC TGA GAG GGG CCG GAC Primer P4:
5′ TCA TTT TCT CTT CCG GCC ACA AGC FISH analysis showed that the BAC hybridised to 7q11.2 and that it was not chimaeric. Vectorette libraries were constructed from EcoRI, EcoRV, RsaI and PvuII-digested BAC DNA and subjected to PCR amplification using a vectorette specific primer and one cDNA primer as described by Riley et al. (15) . Column-purified PCR products were sequenced by direct doublestrand fluorescent cycle sequencing using an ABI 373 sequencer. Intron PCR was carried out using the BCL XL Expand system according to the manufacturer's instructions.
Elastin FISH and microsatellite analysis
Elastin FISH was carried out using the Oncor WSCR probe according to manufacturer's instructions. Intron 18 microsatellite analysis was carried out by PCR amplification of genomic DNA using the following primers: ELN intron 18F: 5′ ATG AGA CGT GGT CAA GGG TAT ELN intron 18R: 5′ GGG ATC CCA GGT GCT GCG GTT All amplifications were carried out using 100 ng of genomic DNA and 10 pmol of each primer in 20 µl reaction volumes. Cycle conditions were: 95_C for 2 min, then 27 cycles of: 94_C for 1 min, 60_C for 1 min and 72_C for 1 min, with a final extension step of 5 min at 72_C. PCR products were electrophoresed on 8% polyacrylamide gels (acrylamide:N,N′ bis-acrylamide 19:1) for 3 h at 300 V then visualised by silver staining.
Mutation detection and sequencing
Exons 21 and 26 of the ELN gene were PCR amplified using the primers listed below and amplification conditions as described above. Mutations were detected by a combination of SSCP and heteroduplex analysis (18) . Briefly, PCR products were run on 1 mm thick non-denaturing 8% polyacrylamide gels (acrylamide:N,N′ bisacrylamide 49:1) at 4_C overnight at a constant 350 V. Products were detected by silver staining. Mutations were initially characterised by direct double-strand cycle sequencing of column-purified PCR products in both orientations with a matched control on a fluorescent sequencer (ABI 373). ELN X21F : 5′ GAG GTC GTA TCC ATG CCT TAC AG  ELN X21R:  5′ TCC AGG CCA TTT CAG TCC TGG AG  ELN X26F:  5′ GGC ATG CTC CCT GCC TGC TGT CG  ELN X26R: 5′ CCC AGA TGC TTA GGA GAA CCT AA
Confirmation of mutations
For confirmation of the exon 21 mutation, HindIII digestion of PCR products was carried out according to manufacturer's instructions (Gibco-BRL). The restriction fragments were separated on a 2% agarose gel and visualised by ethidium bromide staining. For confirmation of the exon 26 mutation, ARMS PCR (19) was carried out using the ELN X26R primer and a primer designed to amplify the mutant allele only: No amplification is obtained in the absence of the mutation, so intron 26 of the elastin gene was used as an internal control for amplification, which gave a 450 bp product. PCR was carried out as above. Cycle conditions were: 95_C for 2 min, then 30 cycles of 94_C for 1 min, 55_C for 1 min and 72_C for 1 min, with a final extension step of 5 min at 72_C. The products were separated on a 2% agarose gel.
